Autel Energy Collaborates with Phoenix Contact to Integrate High-Current CCS2 Technology into New Megawatt-Class Charging System
9.9.2025 09:30:00 CEST | Business Wire | Press Release
As part of its global product launch event “Infinite Power – Starting from Zero,” Autel Energy introduced a high-power charging system from the MaxiCharger DT1000 series, integrating Phoenix Contact’s latest 1,000A liquid-cooled CCS Type 2 cable and connector system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909054584/en/
Autel Energy showcased the MaxiCharger DT1000 terminal integrating Phoenix Contact’s latest liquid-cooled CCS2 cable and connector.
This marks the first integration of Phoenix Contact’s 1,000A CCS2 technology into the MaxiCharger DT1000 series—expanding its capability to serve high-power applications such as heavy-duty vehicles, commercial fleets or even high-performance passenger cars, while enhancing thermal stability and system-level compatibility.
“By integrating Phoenix Contact’s new CCS2 connector into our MaxiCharger DT1000, we can bring this technology into a complete system — from modular cabinets to dispensers — enabling the highest charging performance on CCS where it’s needed today.” said Andreas Lastei, Vice President of Autel Energy Europe. “At the same time, this partnership shows how essential strong collaboration is in our industry. Only by working together can we bring the best solutions to market and make e-mobility truly mass market.”
High-Power Charging with Commercially Proven Standards
Phoenix Contact’s new system is an integrated liquid-cooled cable and connector platform, with optimized conductors and water-glycol cooling loop ensuring stable thermal performance. The cable design supports continuous 800 A and 1,000 A boost operation while remaining lightweight and flexible for operator handling, paired with the connector’s Pt1000 temperature sensors, insulation monitoring, and IP67 protection.
“With the new generation of the cooled CCS HPC connector, Phoenix Contact delivers a charging power of up to 1 MW in boost mode, significantly narrowing the performance gap between CCS and MCS charging stations,” said Dipl.-Ing. Joachim Pucker, Senior Director E-Mobility Sales Network at Phoenix Contact. “While this does not make the MCS standard obsolete, it broadens the application range of CCS-based charging solutions and helps reduce the costs of infrastructure expansion, particularly for long-haul transportation. Together with Autel, we have integrated this technology into the highly efficient MaxiChargers to ensure an optimal charging experience for customers.”
System Architecture and Operational Impact
This product within the MaxiCharger DT1000 series integrates Phoenix Contact’s 1,000 A liquid-cooled CCS2 connector to meet Autel’s design goals in sustained high-current delivery, efficient thermal management, and system-level compatibility. Built on modular power electronics architecture, the system supports flexible scaling from mid-range configurations to megawatt-level deployments, adapting to various site requirements.
Liquid cooling is applied to the connector interface, ensuring stable thermal performance during prolonged high-load operation. The MaxiCharger DT1000 series can be deployed alongside Autel MaxiCharger latest Liquid-Cooled modules — including the MaxiCharger DS600L and DS600/480 — offering flexible system configurations to meet varying site and performance requirements.
Designed for real-world deployment, the MaxiCharger DT1000 series minimizes infrastructure complexity and footprint while maximizing equipment utilization in high-throughput locations such as intercity bus terminals, logistics hubs, and high-throughput fleet depots.
This collaboration highlights how proven high-current CCS2 technology can accelerate infrastructure readiness today, while preparing the industry for the megawatt-class demands of tomorrow. For Autel, it marks another step in building Europe’s most flexible and future-proof charging ecosystem.
About Autel
Autel Europe provides intelligent EV charging solutions for residential, commercial, and public applications. Its MaxiCharger series offers reliable, high-performance AC and DC chargers with a strong focus on safety, interoperability, and ease of deployment. Today, Autel Europe serves customers in 33 countries across the continent, supporting the transition to sustainable mobility with flexible and future-oriented charging infrastructure.
About Phoenix Contact
Phoenix Contact is a global leader in industrial connection and automation technology. The company’s e-mobility division specializes in high-current charging connectors and systems for electric vehicles and infrastructure providers worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909054584/en/
Contacts
Jiaqi Liu
jiaqi.liu@autel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom